Adrian Krainer Net Worth

Adrian Krainer biography

Prof. Adrian R. Krainer Ph.D. serves as Independent Director of the Company. Professor Krainer is the St. Giles Professor at Cold Spring Harbor Laboratory, a biological research institution, where he has served since 1986 and where his work led directly to the invention and development of SPINRAZA. Professor Krainer holds a B.A. in Biochemistry from Columbia University and a Ph.D. in Biochemistry from Harvard University.

What is the salary of Adrian Krainer?

As the Independent Director of Stoke Therapeutics, the total compensation of Adrian Krainer at Stoke Therapeutics is $353,778. There are 10 executives at Stoke Therapeutics getting paid more, with Stephen Tulipano having the highest compensation of $1,176,400.

How old is Adrian Krainer?

Adrian Krainer is 61, he's been the Independent Director of Stoke Therapeutics since 2014. There are 8 older and 12 younger executives at Stoke Therapeutics. The oldest executive at Stoke Therapeutics, Inc. is Dr. Edward M. Kaye M.D., Ph.D., 72, who is the CEO & Director.

What's Adrian Krainer's mailing address?

Adrian's mailing address filed with the SEC is C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD, MA, 01730.

Insiders trading at Stoke Therapeutics

Over the last 5 years, insiders at Stoke Therapeutics have traded over $49,612,288 worth of Stoke Therapeutics stock and bought 4,288,550 units worth $94,976,062 . The most active insiders traders include Group, Llc Green Jeremy Red..., Investments, Lpwong Roderic... és Trust Blue Horizon Enterpri.... On average, Stoke Therapeutics executives and independent directors trade stock every 23 days with the average trade being worth of $1,639,987. The most recent stock trade was executed by Barry Ticho on 3 September 2024, trading 10,000 units of STOK stock currently worth $6,000.

What does Stoke Therapeutics do?

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Stoke Therapeutics executives and stock owners

Stoke Therapeutics executives and other stock owners filed with the SEC include:

• Stephen Tulipano,
  Chief Financial Officer
• Dr. Edward M. Kaye,
  CEO & Director
• Dr. Edward M. Kaye M.D., Ph.D.,
  CEO & Director
• Huw Nash,
  Chief Operating Officer, Chief Business Officer
• Barry Ticho,
  Chief Medical Officer
• Edward Kaye,
  Chief Executive Officer, Director
• Dr. Barry S. Ticho FACC, M.D., Ph.D.,
  Chief Medical Officer
• Stephen J. Tulipano CPA, CPA, MBA,
  Chief Financial Officer
• Seth Harrison,
  Independent Chairman of the Board
• Jennifer Burstein,
  Independent Director
• Adrian Krainer,
  Independent Director
• Arthur Tzianabos,
  Independent Director
• Arthur Levin,
  Independent Director
• Dr. Adrian R. Krainer Ph.D.,
  Co-Founder, Independent Director & Member of Scientific Advisory Board
• Garry Menzel,
  Independent Director
• Julie Smith,
  Independent Director
• Gene Liau,
  Executive Vice President, Head of Research and Preclinical Development
• Dawn Kalmar,
  Chief Communications Officer
• Jonathan Allan J.D.,
  Deputy Gen. Counsel
• Dr. Gene Liau,
  Chief Scientific Officer
• Dr. Huw M. Nash Ph.D.,
  COO & Chief Bus. Officer
• Nancy M. Wyant,
  VP & Head of Clinical Operations
• Shamim Ruff,
  Chief Regulatory Officer
• Joan Wood,
  Head of HR
• Isabel Aznarez Ph.D.,
  Co-Founder, VP & Head of Biology
• Group, Llc Green Jeremy Red...,
  
• Samuel W. Hall,
  Director
• Life Science Ventures, L.P....,
  
• Investments, Lpwong Roderic...,
  
• Robin A. Walker,
  Chief Legal Officer, CCO & Sec
• Jonathan Allan,
  GENERAL COUNSEL & CORP SEC
• Trust Blue Horizon Enterpri...,
  
• Thomas Leggett,
  Chief Financial Officer
• Ian F Smith,